We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

17 hedge funds and large institutions have $37.6M invested in Verona Pharma in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.01% less ownership

Funds ownership: 7.01% → 7% (-0.01%)

6% less funds holding

Funds holding: 18 → 17 (-1)

21% less capital invested

Capital invested by funds: $47.5M → $37.6M (-$9.96M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.37%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
1
Increased
–
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$8.46K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$68K
2
Deutsche Bank
Deutsche Bank
Germany
-$8.54K
3
Renaissance Technologies
Renaissance Technologies
New York
-$8.54K
4
WS
Wedbush Securities
California
-$2.96K
5
TRCT
Tower Research Capital (TRC)
New York
-$634

VRNA Hedge Fund Activity: Q2 2019 in Review

17 of the 4,616 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2019, worth a combined $37.6M — down 21% from $47.5M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of VRNA and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $8.46K. The largest seller was Citadel Advisors, exiting entirely with an estimated $68K sold.

  • 17 institutional investors held Verona Pharma (VRNA) as of Q2 2019, down from 18 in Q1 2019.
  • Funds reported $37.6M of Verona Pharma stock for Q2 2019, down 21% quarter-over-quarter.
  • 1 fund opened new Verona Pharma positions in Q2 2019 and 2 closed out, a net change of -1 holder.
  • The largest Verona Pharma buyer in Q2 2019 was UBS Group, an estimated $8.46K added.
  • The largest Verona Pharma seller in Q2 2019 was Citadel Advisors, an estimated $68K sold.

Based on aggregated 13F filings for Q2 2019.